BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

218 related articles for article (PubMed ID: 32601104)

  • 1. Epigenetic Regulation of Differentially Expressed Drug-Metabolizing Enzymes in Cancer.
    Wang J; Yu L; Jiang H; Zheng X; Zeng S
    Drug Metab Dispos; 2020 Sep; 48(9):759-768. PubMed ID: 32601104
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Role of Drug-metabolizing Enzymes in Cancer and Cancer Therapy.
    Feng S; Li A; Zheng YC; Liu HM
    Curr Drug Metab; 2020; 21(1):67-76. PubMed ID: 31902352
    [TBL] [Abstract][Full Text] [Related]  

  • 3. New Promises to Cure Cancer and Other Genetic Diseases/Disorders: Epi-drugs Through Epigenetics.
    Duan YT; Sangani CB; Liu W; Soni KV; Yao Y
    Curr Top Med Chem; 2019; 19(12):972-994. PubMed ID: 31161992
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Methylation Modification, Alternative Splicing, and Noncoding RNA Play a Role in Cancer Metastasis through Epigenetic Regulation.
    Yu B; Yu X; Xiong J; Ma M
    Biomed Res Int; 2021; 2021():4061525. PubMed ID: 34660788
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Involvement of noncoding RNAs in epigenetic modifications of esophageal cancer.
    Xiao Y; Su M; Ou W; Wang H; Tian B; Ma J; Tang J; Wu J; Wu Z; Wang W; Zhou Y
    Biomed Pharmacother; 2019 Sep; 117():109192. PubMed ID: 31387188
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Infection-associated epigenetic alterations in gastric cancer: New insight in cancer therapy.
    Fattahi S; Kosari-Monfared M; Ghadami E; Golpour M; Khodadadi P; Ghasemiyan M; Akhavan-Niaki H
    J Cell Physiol; 2018 Dec; 233(12):9261-9270. PubMed ID: 30076708
    [TBL] [Abstract][Full Text] [Related]  

  • 7. LncRNA regulation: New frontiers in epigenetic solutions to drug chemoresistance.
    Zhou Y; Sun W; Qin Z; Guo S; Kang Y; Zeng S; Yu L
    Biochem Pharmacol; 2021 Jul; 189():114228. PubMed ID: 32976832
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Interplay between regulation by methylation and noncoding RNAs in cancers.
    Lu CX; Wu XL; Zhang GY; Gu XT; Ma X; He DX
    Eur J Cancer Prev; 2018 Jul; 27(4):418-424. PubMed ID: 29557800
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Molecular Mechanisms of Epigenetic Regulators as Activatable Targets in Cancer Theranostics.
    Li Y; Li Z; Zhu WG
    Curr Med Chem; 2019; 26(8):1328-1350. PubMed ID: 28933282
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Epigenetic regulation in human cancer: the potential role of epi-drug in cancer therapy.
    Lu Y; Chan YT; Tan HY; Li S; Wang N; Feng Y
    Mol Cancer; 2020 Apr; 19(1):79. PubMed ID: 32340605
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Epigenetic Targets and their Inhibitors in Cancer Therapy.
    Zhao L; Duan YT; Lu P; Zhang ZJ; Zheng XK; Wang JL; Feng WS
    Curr Top Med Chem; 2018; 18(28):2395-2419. PubMed ID: 30582481
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Epigenetic perspectives on cancer chemotherapy response.
    Liu MZ; McLeod HL; He FZ; Chen XP; Zhou HH; Shu Y; Zhang W
    Pharmacogenomics; 2014 Apr; 15(5):699-715. PubMed ID: 24798726
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Deciphering the Epigenetic Symphony of Cancer: Insights and Epigenetic Therapies Implications.
    Akram F; Tanveer R; Andleeb S; Shah FI; Ahmad T; Shehzadi S; Akhtar AM; Syed G
    Technol Cancer Res Treat; 2024; 23():15330338241250317. PubMed ID: 38780251
    [TBL] [Abstract][Full Text] [Related]  

  • 14. The role of drug-metabolizing enzymes in synthetic lethality of cancer.
    Zeng Z; Zheng W; Hou P
    Pharmacol Ther; 2022 Dec; 240():108219. PubMed ID: 35636517
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Emerging links between epigenetic alterations and dysregulation of noncoding RNAs in cancer.
    Maruyama R; Suzuki H; Yamamoto E; Imai K; Shinomura Y
    Tumour Biol; 2012 Apr; 33(2):277-85. PubMed ID: 22219034
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Pharmacogenomics, regulation and signaling pathways of phase I and II drug metabolizing enzymes.
    Rushmore TH; Kong AN
    Curr Drug Metab; 2002 Oct; 3(5):481-90. PubMed ID: 12369894
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Role of pharmacogenetics of drug-metabolizing enzymes in treating osteosarcoma.
    Hattinger CM; Serra M
    Expert Opin Drug Metab Toxicol; 2015; 11(9):1449-63. PubMed ID: 26095223
    [TBL] [Abstract][Full Text] [Related]  

  • 18. DNA methylation as a target of epigenetic therapeutics in cancer.
    Li KK; Li F; Li QS; Yang K; Jin B
    Anticancer Agents Med Chem; 2013 Feb; 13(2):242-7. PubMed ID: 22934696
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Molecular targets for epigenetic therapy of cancer.
    Humeniuk R; Mishra PJ; Bertino JR; Banerjee D
    Curr Pharm Biotechnol; 2009 Feb; 10(2):161-5. PubMed ID: 19199948
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Epigenetic regulation of prostate cancer: the theories and the clinical implications.
    Liao Y; Xu K
    Asian J Androl; 2019; 21(3):279-290. PubMed ID: 30084432
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.